Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals

Diabetologia

Volumn 57, Issue 8, 2014, Pages 1720-1725

  Bagger, Jonatan I ^a   Knop, Filip K ^a   Lund, Asger ^a   Holst, Jens J ^a   Vilsbøll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glucagon; Glucose; i.v.; Intravenous; Oral; Type 2 diabetes

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG DOSE INCREASE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLUCAGONEMIA; INSULIN BLOOD LEVEL; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCOSE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; MIDDLE AGED;

EID: 84904740548     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3264-2     Document Type: Article

References (11)

1. Unger RH, Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16
2. Mitrakou A, Kelley D, Veneman T et al (1990) Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-1390 (Pubitemid 20372227)
3. Ipp E (2000) Impaired glucose tolerance: the irrepressible alpha-cell? Diabetes Care 23:569-570
4. Knop FK, Vilsbøll T, Madsbad S et al (2007) Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 50:797-805 (Pubitemid 46355821)
5. Meier J, Deacon C, SchmidtWet al (2007) Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 50:806-813 (Pubitemid 46355834)
6. Bagger JI, Knop FK, Lund A et al (2011) Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96:737-745
7. Holst JJ, Pedersen JH, Baldissera F, Stadil F (1983) Circulating glucagon after total pancreatectomy in man. Diabetologia 25:396-399 (Pubitemid 14235463)
8. Christensen M, Vedtofte L, Holst JJ et al (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60:3103-3109
9. Lund A, Vilsbøll T, Bagger JI et al (2011) The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 300:E1038-E1046
10. Chia CW, Carlson OD, Kim W et al (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58:1342-1349
11. Jackson RS, Creemers JWM, Farooqi IS et al (2003) Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 112:1550-1560 (Pubitemid 38056281)